Bolt Biotherapeutics holders back board, auditor

Bolt Biotherapeutics, Inc. reported the results of its 2026 annual stockholder meeting.

Accepted by SEC EDGAR 06/11/2026 - 04:05 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Bolt Biotherapeutics, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected William P. Quinn and Jakob Dupont, M.D. as Class II directors to serve until the 2029 annual meeting or until a successor is chosen.

A total of 1,921,567 common shares were entitled to vote as of April 22, 2026, with 877,358 shares represented in person or by proxy. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares entitled to vote: 1,921,567 shares Shares represented at meeting: 877,358 shares Votes for Quinn: 349,358 votes +3 more

6 metrics

Shares entitled to vote 1,921,567 shares Common stock entitled to vote as of April 22, 2026

Shares represented at meeting 877,358 shares Shares present in person or by proxy at 2026 annual meeting

Votes for Quinn 349,358 votes Election of William P. Quinn as Class II director

Votes for Dupont 377,163 votes Election of Jakob Dupont, M.D. as Class II director

Auditor ratification votes for 768,336 votes Ratification of PricewaterhouseCoopers LLP for year ending December 31, 2026

Auditor ratification votes against 107,471 votes Ratification of PricewaterhouseCoopers LLP

Key Terms

broker non-votes, independent registered public accounting firm, proxy statement, emerging growth company

4 terms

broker non-votes financial

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

proxy statement regulatory

"each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

emerging growth company regulatory

"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bolt Biotherapeutics (BOLT) announce in this 8-K filing?

Bolt Biotherapeutics reported the results of its 2026 annual stockholder meeting. Shareholders elected two Class II directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.

How many Bolt Biotherapeutics (BOLT) shares were entitled to vote at the 2026 meeting?

A total of 1,921,567 shares of Bolt Biotherapeutics common stock were entitled to vote as of April 22, 2026. Of these, 877,358 shares were represented in person or by proxy at the 2026 annual meeting.

Which directors were elected at Bolt Biotherapeutics’ 2026 annual meeting?

Stockholders elected William P. Quinn and Jakob Dupont, M.D. as Class II directors. They will serve until the company’s 2029 annual meeting of stockholders, or until a successor is duly elected and qualified, or their earlier death, resignation or removal.

What were the vote results for Bolt Biotherapeutics director William P. Quinn?

William P. Quinn received 349,358 votes for election and 52,117 votes withheld, with 475,883 broker non-votes. These results confirmed his election as a Class II director at the 2026 annual meeting of stockholders.

Did Bolt Biotherapeutics (BOLT) stockholders ratify the company’s auditor for 2026?

Yes. Stockholders ratified PricewaterhouseCoopers LLP as Bolt Biotherapeutics’ independent registered public accounting firm for the year ending December 31, 2026, with 768,336 votes for, 107,471 votes against, and 1,551 votes abstaining.

What was the level of participation at Bolt Biotherapeutics’ 2026 annual meeting?

Out of 1,921,567 shares entitled to vote, 877,358 shares were represented in person or by proxy. This represented the voting base used to decide the director elections and auditor ratification at the 2026 annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 10, 2026

    

BOLT BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39988	47-2804636
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

900 Chesapeake Drive
Redwood City, California		94063
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: (650) 665-9295

    

     Not Applicable

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.00001 per share	BOLT	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2026, Bolt Biotherapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 28, 2026. A total of 1,921,567 shares of the Company's common stock were entitled to vote as of April 22, 2026, the record date for the Annual Meeting, of which 877,358 shares were represented in person or by proxy at the Annual Meeting. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management’s solicitation.

The following director nominees were elected to serve as Class II members of the Company’s board of directors until the Company’s 2029 Annual Meeting of Stockholders, or until their respective successor is duly elected and qualified, or until their respective death, resignation or removal:


Nominee	Votes For		Votes Withheld		Broker Non-Votes
William P. Quinn		349,358		52,117		475,883
Jakob Dupont, M.D.		377,163		24,312		475,883

The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified.


Votes For		Votes Against		Votes Abstaining
	768,336		107,471		1,551

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			Bolt Biotherapeutics, Inc.

Date:	June 11, 2026	By:	/s/ William P. Quinn
			William P. Quinn President, Chief Executive Officer and Chief Financial Officer (Principal Executive and Financial Officer)

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document